Aripiprazole Lauroxil
ApprovedTerminated 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Jan 23, 2024 → Mar 3, 2025
NCT ID
NCT05662306About Aripiprazole Lauroxil
Aripiprazole Lauroxil is a approved stage product being developed by Alkermes for Schizophrenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT05662306. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05662306 | Approved | Terminated |
| NCT02636842 | Phase 1 | Completed |
| NCT02634320 | Approved | Completed |
| NCT02320032 | Phase 1 | Completed |
Competing Products
20 competing products in Schizophrenia